Acyclovir Resistance

FDA's approval of Hovilpri highlights concerns about acyclovir resistance in treating herpes in immunocompromised adults, underscoring the need for innovative therapies.

FDA Approves Hovilpri for Herpes Lesions Resistant to Antiviral Treatment in Immunocompromised Adults

Published on 10/10/2026